Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma

Cancer

Volumn 86, Issue 7, 1999, Pages 1368-1376

  Akpek, Gorgun ^a   Koh, Howard K ^b   Bogen, Steven ^c   O'Hara, Carl ^c   Foss, Francine M ^d  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TUFTS MEDICAL CENTER   (United States)

Author keywords

Cutaneous lymphoma; Medical oncology; Mycosis fungoides; Treatment

Indexed keywords

COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEZARY SYNDROME; SKIN LYMPHOMA; SUPRAVENTRICULAR TACHYCARDIA; T CELL LYMPHOMA; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FEMALE; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; PREDNISONE; REMISSION INDUCTION; SEZARY SYNDROME; VINCRISTINE;

EID: 0033214877     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19991001)86:7<1368::AID-CNCR37>3.0.CO;2-8     Document Type: Article

References (45)

1. Block J, Edgecomb J, Eisen A. Mycosis fungoides: natural history and aspects of its relationship to other malignant lymphomas. Am J Med 1963;24:228-35.
2. Lutzner M, Edelson R, Schein P, Green I, Kirkpatrick C, Ahmed A. Cutaneous T-cell lymphoma: the Sézary syndrome, mycosis fungoides, and related disorders. Ann Intern Med 1975;83:534-52.
3. Rappaport H, Thomas LB. Mycosis fungoides: the pathology of extracutaneous involvement. Cancer 1974;34:1198-229.
4. Long J, Mihm M. Mycosis fungoides with extracutaneous dissemination. Cancer 1974;34:1745-55.
5. Van Leeuwen A, Meijer C, DeMan J. T-cell membrane characteristics of mycosis cells in the skin and lymph node. J Invest Dermatol 1975;65:367-9.
6. Broder S, Edelson RL, Lutzner MA, Nelson DL, MacDermott RP, Durm ME, et al. The Sézary syndrome: a malignant proliferation of helper T-cells. J Clin Invest 1976;58:1279-306.
7. Vonderheid EC, Tan ET, Kantor AF, Shrager L, Micaily B, Van Scott EJ. Long term efficacy, curative potential, and carcinogenicity of typical mechlorethamine chemotherapy in cutaneous T-cell lymphoma. J Am Acad Dermatol 1989; 20:416-28.
8. Hoppe RT, Cox RS, Fuks Z, Price NM, Bagshaw MA, Farber EM. Electron beam therapy for mycosis fungoides: the Stanford experience. Cancer Treat Rep 1979;63:691-700.
9. Roenigk HH Jr., Kuzel TM, Skoutelis AP, Springer E, Yu G, Caro W, et al. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma. J Invest Dermatol 1990;95:198S-205S.
10. Bunn PA Jr., Foon KA, Ihde DC, Longo DL, Eddy J, Winkler CF, et al. Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas. Ann Intern Med 1984;101:484-7.
11. Bunn PA, Ihde DC, Foon KA. The role of recombinant interferon alpha-2a in the therapy of cutaneous T-cell lymphomas. Cancer 1986;57:1689-95.
12. Tura S, Mazza P, Zinzani PL, Ghetti PL, Poletti G, Gherlinzoni F, et al. Alpha recombinant interferon in the treatment of mycosis fungoides. Haematologica 1987;72:337-40.
13. Vonderheid EC, Thompson R, Smiles KA, Lattanand A. Recombinant interferon alpha-2b in plaque phase mycosis fungoides. Intralesional and low-dose intramuscular therapy. Arch Dermatol 1987;123:757-63.
14. Olsen EA, Rosen ST, Vollmer RT, Variakojis D, Roenigk HH Jr., Diab N, et al. Interferon alpha-2a in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 1989;20: 395-407.
15. Papa G, Tura S, Mandelli F, Vegna ML, Defazio D, Mazza P, et al. Is interferon alpha in cutaneous T-cell lymphoma a treatment of choice? Br J Haematol 1991;79:48-51.
16. Vegna ML, Papa G, Defazio D, Pisani F, Coppola G, De Pita O, et al. Interferon alpha-2a in cutaneous T-cell lymphoma. Eur J Hematol 1990;52:32-5.
17. Kohn EC, Steis RG, Sausville EA, Veach SR, Stocker JL, Phelps R, et al. Phase II trial of intermittent high dose recombinant interferon alpha-2a in mycosis fungoides and the Sézary syndrome. J Clin Oncol 1990;8:155-60.
18. Diamandidou E, Cohen PR, Kurzrock R. Mycosis fungoides and Sézary syndrome. Blood 1996;88:2385-409.
19. Kaye FJ, Bunn PA Jr., Steinberg SM, Stocker JL, Ihde DC, Fischmann AB, et al. A randomized trial comparing combination electron beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989;321:1784-90.
20. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989;81:116-20.
21. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verepamil. J Clin Oncol 1991;9:17-24.
22. Pileri SA, Sabattini E, Falini B, Tazzari PL, Gherlinzoni F, Michieli MG, et al. Immunohistochemical detection of the multidrug transport protein p170 in human normal tissues and malignant lymphomas. Histopathology 1991;19: 131-40.
23. Lai GM, Chen YN, Mickley LA, Fojo AT, Bates SE. P-glycoprotein expression and schedule dependence of Adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer 1991;49:696-703.
24. Wilson WH, Bryant G, Bates S, Fojo A, Wittes RE, Steinberg SM, et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 1993;11:1573-82.
25. Bunn P, Lamberg S. Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas. Cancer Treat Rep 1979;63:725-8.
26. Sausville EA, Worsham GF, Matthews MJ, Makuch RW, Fischmann AB, Schechter GP, et al. Histologic assessment of lymph nodes in mycosis fungoides/Sézary syndrome (cutaneous T-cell lymphoma): clinical correlations and prognostic import of a new classification system. Hum Pathol 1985; 16:1098-109.
27. Sausville EA, Eddy JL, Makuch RW, Fischmann AB, Schechter GP, Matthews M, et al. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups. Ann Intern Med 1988;109:372-82.
28. Dmitrovsky E, Matthews MJ, Bunn PA, Schechter GP, Makuch RW, Winkler CF, et al. Cytologic transformation in cutaneous T-cell lymphoma: a clinicopathologic entity associated with poor prognosis. J Clin Oncol 1987;5:208-15.
29. Common toxicity criteria for cancer clinical trials. In: Wittes R, editor. Manual of oncologic therapeutics. Philadelphia: Lippincott, 1991:445-8.
30. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958:53:457-81.
31. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II Analysis and examples. Br J Cancer 1977;35:1-39.
32. Zic JA, Miller JL, Stricklin GP, King LE Jr. The North American experience with photopheresis. Ther Apher 1999;3:50-62.
33. Kuzel TM, Roenigk HH, Rosen ST. Mycosis fungoides and the Sézary syndrome: a review of pathogenesis, diagnosis, and therapy. J Clin Oncol 1991;9:1298-313.
34. Kenime DJ, Bunn PA. State of the art therapy of mycosis fungoides and Sézary syndrome. Oncology 1992;6:31-42.
35. Bunn PA Jr., Hoffman SJ, Norris D, Golitz LE, Aeling JL. Systemic therapy of cutaneous T-cell lymphoma (mycosis fungoides and the Sézary syndrome). Ann Intern Med 1994; 121:592-602.
36. Rosen ST, Foss FM. Chemotherapy for mycosis fungoides and the Sézary syndrome. Cutaneous t-cell lymphoma. Hematol Oncol Clin North Am 1995;9:1109-16.
37. Grozea PN, Jones SE, McKelvey EM, Coltman CA Jr., Fisher R, Haskins CL. Combination chemotherapy for mycosis fungoides: a Southwest Oncology Group study. Cancer Treatment Rep 1979;63:647-53.
38. Jackson DV Jr., Paschold EH, Spurr CL, Muss HB, Richards F II, Cooper MR, et al. Treatment of advanced non-Hodgkin's lymphoma with vincristine infusion. Cancer 1984;53:2601-6.
39. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984;310:1353-6.
40. Beljaards RC, Kaudewitz P, Berti E, Gianotti R, Neumann C, Rosso R, et al. Primary cutaneous CD30-positive large cell lymphoma: definition of a new type of cutaneous lymphoma with favorable prognosis. Cancer 1993;71: 2097-104.
41. Paulli M, Berti E, Rosso R, Boveri E, Kindl S, Klersy C, et al. CD30/Ki-1-positive lymphoproliferative disorders of the skin - clinicopathological correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and Treatment of Cancer, Cutaneous Lymphoma Project Group. J Clin Oncol 1995;13:1343-54.
42. Redman JR, Cabanillas F, Velasquez WS, McLaughlin P, Hagemeister FB, Swan F Jr., et al. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low grade lymphoma. J Clin Oncol 1992;10:790-4.
43. Wijermans P, Gerrits W, Haak H. Severe immunodeficiency in patients treated with fludarabine monophosphate. Eur J Hematol 1993;50:292-6.
44. Foss FM, Ihde DC, Linnoila IR, Fischmann AB, Schechter GP, Cotelingam JD, et al. Phase II trial of fludarabine phosphate and interferon alpha-2a in advanced mycosis fungoides/Sézary syndrome. J Clin Oncol 1994;12:2051-9.
45. Marolleau JP, Baccard M, Flageul B, Rybojad M, Laroche L, Verola O, et al. High-dose recombinant interleukin-2 in advanced cutaneous T-cell lymphoma. Arch Dermatol 1995; 131:574-9.